News | Radiopharmaceuticals and Tracers | October 28, 2019

Breakthrough has potential to transform medical isotope production, solve a global healthcare shortage

 Phoenix’s fusion neutron generation technology.

October 28, 2019 — Phoenix LLC and Shine Medical Technologies LLC, nuclear technology companies focused on near-term fusion applications and medical isotope production, announced in early October the achievement of a new world record for a nuclear fusion reaction in a steady-state system, the strongest of its kind ever produced on Earth. The reaction yielded 46 trillion (4.6 x 1,013) neutrons per second, eclipsing the previous record by nearly 25 percent and setting a new standard for neutron generator technology that is expected to enable further advances in medicine, manufacturing and clean energy.

The world record was achieved in late July during a demonstration of Phoenix’s third-generation gas-target neutron generator as part of the companies’ ongoing preparation for full-scale operation of the medical isotope production facility being built by Shine. The previous steady-state fusion record was held by the Rotating Target Neutron Source II facility in Livermore, Calif., which operated from 1978 to 1987. It produced a maximum output of 37 trillion (3.7 x 1,013) neutrons per second.

The record-setting fusion reaction followed a demonstration in June of the neutron generator, during which Phoenix and Shine ran a 132-hour (5.5 days) test with more than 99 percent uptime. These successful tests validated the performance and reliability of the Phoenix neutron generator technology that will drive Shines’s production of molybdenum-99 (Mo-99) and other isotopes. Shine anticipates that isotope production will begin in 2021.

“This achievement of producing the strongest sustained nuclear fusion reaction ever created by humans cements Phoenix’s status as the world leader in fusion neutron generation technology,” said Ross Radel, CEO of Phoenix. “The positive impacts that this now fully-proven technology will have to our customers like SHINE in health care and others working to develop 100-percent clean and abundant fusion energy are tremendous. I could not be prouder of our extremely dedicated team that has worked for over a decade to achieve this result.”  

Since 2005, the two companies have operated under the mission established by Dr. Greg Piefer, Shine’s CEO and founder, and the founder and former CEO of Phoenix, to use fusion technology to solve near-term problems caused by limited accessibility to nuclear reactors for applications such as medical isotope production, non-destructive testing and materials research with the long-term vision using those innovations to further fusion science to make the world a better place.

“The world-record proves the accelerator technology is suitable to produce medical isotopes at the scale required to support a robust business case,” Piefer said. “It is also a steppingstone toward advancing fusion for other, more ambitious applications, including the recycling of nuclear waste and ultimately the creation of cleaner, safer and more abundant energy.”

Shine’s facility will integrate eight Phoenix systems to drive Shine’s Mo-99 production, which could eliminate the use of reactor facilities, while removing weapons-grade uranium from the world by using uranium that’s been made safe by the federal government as a consumable in its process.

Once operations begin, Shine will be capable of producing enough isotopes to satisfy one-third of global demand. Chronic global shortages routinely and significantly affect the diagnosis and treatment of patients around the world. This new source of Mo-99 is projected to improve the lives of more than 1 billion people during the next 50 years.

Torion Plasma Corp. provided expertise on tritium gas handling, an important element of neutron generation by the system.

 

The Need for Medical Isotopes

Medical isotopes are radioisotopes that are used in the diagnosis and treatment of disease. Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium 99m (Tc-99m). The workhorse of nuclear medicine, Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and to stage cases of cancer. SHINE was founded to deploy a safe, cost-effective, and environmentally-friendly technology to produce a variety of medical isotopes, including Mo‑99. Roughly one percent of all Mo-99 in the world decays every hour, meaning it must be produced continuously. Current production is limited to only a handful of government-owned nuclear research reactors, the majority of which are overseas.

For more information: phoenixwi.com, shinemed.com

 

Related Shine Isotope Production News:

Shine Medical Approved to Build Domestic Molybdenum-99 Production Facility

BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method

Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility
 


Related Content

News | Proton Therapy

November 25, 2022 — Researchers at the University of Wisconsin–Madison, the first U.S. clinical evaluation site for GE ...

Time November 25, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

November 21, 2022 — You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering ...

Time November 21, 2022
arrow
News | RSNA

November 21, 2022 — Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen ...

Time November 21, 2022
arrow
News | Radiopharmaceuticals and Tracers

November 15, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time November 15, 2022
arrow
News | Radiopharmaceuticals and Tracers

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Time November 05, 2022
arrow
Feature | Contrast Media | By Shankar Khatkale

According to a recent study from market research firm Graphical Research, the global imaging agents market size is set ...

Time November 02, 2022
arrow
News | PET Imaging

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 25, 2022
arrow
News | PET Imaging

October 20, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B ...

Time October 20, 2022
arrow
News | SPECT-CT

October 18, 2022 — Spectrum Dynamics announced its newest development in digital nuclear medicine imaging: the ...

Time October 18, 2022
arrow
Subscribe Now